Anika Therapeutics, Inc., a leader in osteoarthritis pain management and regenerative solutions, announced the granting of non-statutory stock options to a newly hired non-executive employee. On June 2, 2025, the company granted options covering a total of 2,500 shares of common stock, with an exercise price set at $11.45 per share, matching the closing price on the Nasdaq Global Select Market on the grant date. This grant, made under Anika's 2021 Inducement Plan, was approved by the compensation committee of the board of directors. The stock options are set to vest over three years, with one-third vesting on each anniversary of the grant, contingent upon continued service with Anika. The options will expire ten years from the grant date unless terminated earlier according to their terms.